Polyclonal Antibody Market Global Share Reach US$ 1,350.0 Million by 2027

Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Polyclonal antibodies are used in general research applications. Moreover, increasing incidence of cancer across the globe is expected to boost the market growth. According to an article published by Cancer Research UK in 2015, 55,122 new cases of breast cancer were registered in 2015. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/4347

The global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Figure 1. Global Polyclonal Antibody Market Share (%), by Region, 2020

Rising cases of infectious diseases are expected to propel growth of the global polyclonal antibody market.

Rising incidence of infectious diseases such as Ebola virus worldwide, especially in under-developed countries, is expected to drive the market growth during the forecast period. For instance, according to an article published by the World Health Organization (WHO) in February 2020, the outbreak of Ebola virus in West Africa was the largest outbreak during 2014-2016 and it still continues in various countries. The facts and figures are given below:

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4347

Figure 2. Global Polyclonal Antibody Market Share (%), by Type, 2020

The ongoing development of polyclonal antibodies in North America is expected to drive the market growth.

North America is expected to hold dominant position in the global polyclonal antibody market owing to ongoing research and development in the region. For instance, in August 2018, SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced that its anti-Ebola immunotherapy, SAB-139, offers100% protection against a lethal dose of the Ebola virus in an animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

Lockdowns in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is expected to limit growth of the global polyclonal antibody market during the forecast period.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/polyclonal-antibody-market-3607

Key Players

Major players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB., and GeneTex, Inc. among others.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837